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Lorenz Räber, MD,* Sigmund Silber, MD,z Patrick W. Serruys, MD,x Peter Jüni, MD,k Stephan Windecker, MD*ABSTRACTFro
an
Ge
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resOBJECTIVES The purpose of this study was to compare the 2-year safety and effectiveness of new- versus early-
generation drug-eluting stents (DES) according to the severity of coronary artery disease (CAD) as assessed by the
SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score.
BACKGROUND New-generation DES are considered the standard-of-care in patients with CAD undergoing percuta-
neous coronary intervention. However, there are few data investigating the effects of new- over early-generation DES
according to the anatomic complexity of CAD.
METHODS Patient-level data from 4 contemporary, all-comers trials were pooled. The primary device-oriented clinical
endpoint was the composite of cardiac death, myocardial infarction, or ischemia-driven target-lesion revascularization
(TLR). The principal effectiveness and safety endpoints were TLR and deﬁnite stent thrombosis (ST), respectively.
Adjusted hazard ratios (HRs) with 95% conﬁdence intervals (CIs) were calculated at 2 years for overall comparisons, as
well as stratiﬁed for patients with lower (SYNTAX score #11) and higher complexity (SYNTAX score >11).
RESULTS A total of 6,081 patients were included in the study. New-generation DES (n ¼ 4,554) compared with early-
generation DES (n ¼ 1,527) reduced the primary endpoint (HR: 0.75 [95% CI: 0.63 to 0.89]; p ¼ 0.001) without
interaction (p ¼ 0.219) between patients with lower (HR: 0.86 [95% CI: 0.64 to 1.16]; p ¼ 0.322) versus higher CAD
complexity (HR: 0.68 [95% CI: 0.54 to 0.85]; p ¼ 0.001). In patients with SYNTAX score >11, new-generation DES
signiﬁcantly reduced TLR (HR: 0.36 [95% CI: 0.26 to 0.51]; p < 0.001) and deﬁnite ST (HR: 0.28 [95% CI: 0.15 to 0.55];
p < 0.001) to a greater extent than in the low-complexity group (TLR pint ¼ 0.059; ST pint ¼ 0.013). New-generation
DES decreased the risk of cardiac mortality in patients with SYNTAX score >11 (HR: 0.45 [95% CI: 0.27 to 0.76];
p ¼ 0.003) but not in patients with SYNTAX score #11 (pint ¼ 0.042).
CONCLUSIONS New-generation DES improve clinical outcomes compared with early-generation DES, with a greater
safety and effectiveness in patients with SYNTAX score >11. (J Am Coll Cardiol Intv 2015;8:1657–66) © 2015 by the
American College of Cardiology Foundation.m the *Department of Cardiology, Bern University Hospital, Bern, Switzerland; yInstitute of Social and Preventive Medicine
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1658D rug-eluting stents (DES) have im-proved outcomes compared withbare-metal stents among patients
undergoing percutaneous coronary interven-
tion (PCI) owing to potent reduction of neo-
intimal hyperplasia and the need for repeat
revascularization (1). Early-generation DES
delayed arterial healing of the stented
segment and, as a result, were associatedwith an increased risk of stent-related thrombotic
events and late restenosis (2,3). New-generation
DES were introduced featuring thinner stent struts,
more biocompatible durable or biodegradable poly-
mer coatings, different antiproliferative agents,
and lower drug loads (4). These reﬁnements trans-
lated into improved clinical outcomes, and new-
generation DES are the current standard of care (5–9).SEE PAGE 1667The likelihood of treatment failure directly cor-
relates with the complexity of underlying coronary
artery disease (CAD). In the large-scale SYNTAX
(Synergy between Percutaneous Coronary Interven-
tion with Taxus and Cardiac Surgery) trial comparing
early-generation paclitaxel-eluting stents with coro-
nary artery bypass surgery (CABG) among patients
with multivessel disease, PCI was inferior in terms of
the composite of cardiovascular death, myocardial
infarction, and repeat revascularization in the over-
all cohort, and differences were particularly pro-
nounced among patients with increased SYNTAX
score (10). Similarly, PCI with the use of early-
generation sirolimus- or paclitaxel-eluting stents
was inferior compared with CABG among diabetic
patients with multivessel disease in the randomized
FREEDOM (Future Revascularization Evaluation in
Patients with Diabetes Mellitus: Optimal Manage-
ment of Multivessel Disease) trial (11). Currently, it is
not well established whether the clinical beneﬁts of
new- over early-generation DES are inﬂuenced by
the anatomic complexity of CAD. We, therefore,
sought to investigate the safety and effectiveness of
new- compared with early-generation DES ines from Medtronic and Biotronik. Dr. Franzone is the recipi
ular research. Dr. Jüni has received research grants to the institu
li Lilly, and The Medicines Company; and is an unpaid steering co
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oston Scientiﬁc, Medtronic, Eli Lilly, and AstraZeneca. All other a
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received July 20, 2015; accepted August 3, 2015.relation to anatomic CAD complexity—deﬁned by the
SYNTAX score—in a large, broadly inclusive popula-
tion of PCI patients enrolled in 4 all-comers ran-
domized clinical trials.
METHODS
STUDY POPULATION. We pooled individual patient-
level data from 4 randomized clinical studies:
the SIRTAX (Sirolimus-Eluting and Paclitaxel-
Eluting Stent for Coronary Revascularization) trial
(NCT00297661) (12), the LEADERS (Limus Eluted from
A Durable versus ERodable Stent coating) trial
(NCT00389220) (13), the RESOLUTE All Comers (Ran-
domized Comparison of a Zotarolimus-Eluting Stent
with an Everolimus-Eluting Stent for Percutaneous
Coronary Intervention) trial (NCT00617084) (14), and
the BIOSCIENCE (Ultrathin Strut Biodegradable Poly-
mer Sirolimus-Eluting Stent Versus Durable Polymer
Everolimus-Eluting Stent for Percutaneous Coronary
Revascularization) trial (NCT01443104) (15). All trials
had an all-comers design and were conducted be-
tween 2004 and 2013 at European institutions, with the
exclusive use of DES. Early-generation DES including
sirolimus-eluting (Cypher or Cypher Select, Cordis,
Miami Lakes, Florida) and paclitaxel-eluting stents
(Taxus, Boston Scientiﬁc, Natick, Massachusetts) were
investigated in the SIRTAX and LEADERS trials (12,13).
New-generation DES encompassing everolimus-eluting
(Xience V or Prime or Xpedition, Abbott Vascular,
Santa Clara, California), zotarolimus-eluting (Resolute,
Medtronic Inc., Santa Rosa, California), biodegradable
polymer biolimus-eluting (BioMatrix Flex, Biosensors
Inc., Newport Beach, California), and biodegradable
polymer sirolimus-eluting stents (Orsiro, Biotronik AG,
Bülach, Switzerland) were evaluated in the LEADERS,
RESOLUTE All Comers, and BIOSCIENCE trials (13–15).
Details on study designs and trial results were reported
elsewhere (12–16). Brieﬂy, patients with either stable
CAD or acute coronary syndrome were eligible if they
had at least 1 lesion with a diameter stenosis$50% in a
vessel with reference diameter of 2.25 to 4.0 mm
(SIRTAX, RESOLUTE All Comers, and BIOSCIENCE
trials) or 2.25 to 3.5 mm (LEADERS trial). Inclusionent of a research grant of Veronesi Foundation–
tion from AstraZeneca, Biotronik, Biosensors Inter-
mmittee or statistical executive committee member
, Biotronik, St. Jude Medical, and The Medicines
om Biotronik, Abbott, Boston Scientiﬁc, Biosensors,
r fees from AstraZeneca, Eli Lilly, Abbott, Biosensors,
uthors have reported that they have no relationships
FIGURE 1 SYNTAX Score Distribution Across Included Randomized Trials
*Mean differences were calculated with the 1-way analysis of variance using the Bonferroni multiple comparison test. BIOSCIENCE ¼ Ultrathin
Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascu-
larization; LEADERS ¼ Limus Eluted from A Durable versus ERodable Stent coating; RESOLUTE All Comers ¼ Randomized Comparison of a
Zotarolimus-Eluting Stent with an Everolimus-Eluting Stent for Percutaneous Coronary Intervention; SIRTAX ¼ Sirolimus-Eluting and
Paclitaxel-Eluting Stent for Coronary Revascularization; SYNTAX ¼ Synergy between Percutaneous Coronary Intervention with Taxus and
Cardiac Surgery.
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1659criteria were broad to reﬂect routine clinical practice.
None of the trials imposed any restriction with respect
to number of treated lesions, treated vessels, lesion
length, or number of stents implanted. The main in-
clusion and exclusion criteria for each trial are re-
ported in the Online Table 1. For the purpose of the
present study, we excluded patients with prior coro-
nary artery bypass grafting (CABG) or patients inwhom
the SYNTAX score was unavailable.
All trials complied with the Declaration of Helsinki,
and the study protocols were approved by the ethics
committees at each study center. All patients pro-
vided written, informed consent for participation in
the individual studies.
SYNTAX SCORE. All baseline coronary lesions with a
diameter stenosis $50% in a vessel with reference
diameter $1.5 mm were included for the assessment
of the SYNTAX score. The score algorithm was
described in full elsewhere and is freely available on
the web site (17). In the LEADERS and RESOLUTE
trials, all of the angiographic variables needed to
derive the SYNTAX score were prospectively
collected by a team of 2 core laboratory analysts. In
contrast, the SYNTAX score was retrospectively
assessed in the SIRTAX and BIOSCIENCE trials by 2experienced interventional cardiologists. At the time
of SYNTAX score calculation, all investigators were
blinded to patient data, and in case of disagreement,
the opinion of a third analyst was acquired and the
ﬁnal decision was made by consensus.
ENDPOINT DEFINITIONS. The primary, device-
oriented clinical endpoint of this study was the
composite of cardiac death, nonfatal myocardial
infarction, or ischemia-driven target lesion revascu-
larization (TLR). The principal effectiveness and safety
endpoints were TLR and deﬁnite stent thrombosis
(ST), respectively. Secondary endpoints included each
individual component of the composite endpoint,
target vessel revascularization (TVR), and the com-
posite of deﬁnite or probable ST. Stent thrombosis was
deﬁned according to Academic Research Consortium
criteria in all trials (18). Endpoint deﬁnitions were
comparable across the 4 trials, and a blinded clinical
events committee independently adjudicated all
adverse events for each trial.
STATISTICAL ANALYSIS. Continuous variables are
presented as mean  SD (or as median with inter-
quartile range) and were compared with independent
samples Student t test. Categorical variables are
TABLE 2 Angiographic and Procedural Characteristics
New-Generation
DES
(n ¼ 4,554)
Early-Generation
DES
(n ¼ 1,527) p Value
GPI use* 675 (14.8) 435 (28.5) <0.001
No. of treated lesions per patient† 1.48  0.75 1.41  0.66 0.043
Multivessel treatment per patient* 1,076 (23.6) 277 (18.1) <0.001
Lesions, n 6,764 2,152
Target vessel location per lesion <0.001
Right coronary artery 2,169 (32.2) 724 (33.6)
Left main artery 75 (1.1) 12 (0.6)
Left anterior descending artery 2,885 (42.8) 975 (45.3)
Left circumﬂex artery 1,610 (23.9) 441 (20.5)
Bypass graft 4 (0.1) 0 (0.0)
De novo lesion per lesion 6,289 (93.8) 2,061 (95.9) 0.001
Occlusion per lesion 640 (9.6) 148 (6.9) <0.001
Stents per lesion 1.32  0.67 1.20  0.56 <0.001
Total stent length per lesion, mm 25.29  15.66 21.20  12.58 <0.001
Mean stent diameter per lesion, mm 2.99  0.46 2.90  0.44 <0.001
Values are n (%) or mean  SD. The p values comparing new- versus early-generation DES are from p values from
models accounting for lesions clustered within patients using robust standard errors. *p values from logistic
regression. †p value from Poisson regression.
DES ¼ drug-eluting stent(s); GPI ¼ glycoprotein IIb/IIIa inhibitors.
TABLE 1 Baseline Clinical Characteristics
New-Generation
DES
(n ¼ 4,554)
Early-Generation
DES
(n ¼ 1,527) p Value
Age, yrs 64.5  11.2 62.7  11.1 <0.001
Female 1,117 (24.5) 380 (24.9) 0.78
Body mass index, kg/m2 27.7  4.4 27.4  4.2 0.06
Diabetes 1,012 (22.2) 298 (19.5) 0.03
Insulin-requiring 330 (7.2) 101 (6.6) 0.42
Hypertension 3,160 (69.4) 998 (65.4) 0.003
Hypercholesterolemia 2,915 (64.0) 934 (61.2) 0.05
Renal failure* 625 (14.3) 172 (13.3) 0.39
GFR, ml/min 85.2  29.2 85.2  25.4 0.92
Current smoker 1,317 (28.9) 512 (34.3) <0.001
Family history of CAD 1,347 (31.8) 606 (39.7) <0.001
Previous MI 1,043 (23.1) 432 (28.3) <0.001
Previous PCI 1,297 (28.5) 387 (25.3) 0.02
Left ventricular ejection
fraction, %
56.1  11.8 56.4  11.7 0.48
Clinical presentation 0.01
Stable CAD 1,752 (40.6) 648 (42.4) 0.22
NSTE-ACS 1,678 (38.9) 528 (34.6) 0.003
ST-segment elevation MI 887 (20.5) 351 (23.0) 0.05
SYNTAX score 13.3  8.9 12.5  8.0 0.003
#22 3,867 (84.9) 1,350 (88.4)
23-32 530 (11.6) 147 (9.6)
>32 157 (3.4) 30 (2.0)
Values are mean  SD or n (%). *Deﬁned as GFR <60 ml/min.
CAD ¼ coronary artery disease; DES ¼ drug-eluting stent(s); GFR ¼ glomerular ﬁltration rate;
MI ¼ myocardial infarction; NSTE-ACS ¼ non–ST-segment elevation acute coronary syndrome;
PCI ¼ percutaneous coronary intervention; SYNTAX ¼ Synergy between Percutaneous Coronary
Intervention with Taxus and Cardiac Surgery.
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1660expressed as counts and percentages and were
compared with chi-square or Fisher exact tests as
appropriate. Baseline lesion variables were analyzed
using general or generalized linear mixed models,
accounting for lesions nested within patients.
Clinical outcomes at 2 years were expressed as
counts with incidence rates computed according to
the Kaplan-Meiermethod. Cox regression analysis was
used to calculate hazard ratios (HRs) with 95% conﬁ-
dence intervals (CIs). Adjusted hazard ratios (HRadj)
were derived from multiple imputation estimated Cox
regressions (20 datasets created using chained equa-
tions and estimates combined using the Rubin’s rule),
adjusting for baseline variables associated with the
primary composite endpoint (age, diabetes, renal
failure, or previous myocardial infarction). Two deﬁ-
nitions of anatomical CAD complexity were applied.
Patients were categorized into low or high CAD
complexity according to the median SYNTAX score (11)
observed in the study population. To evaluate the
possibility that the differences in outcomes between
new- and early-generation DES were due to categori-
zation, we also analyzed SYNTAX scores as a contin-
uous variable. We tested the interaction between the
type of DES (new- vs. early-generation DES) and
the SYNTAX score (after logarithm transformation) in
the Cox-regression analyses and graphically repre-
sented the results with spline curves by using a ﬂex-
ible model (xblc command). All analyses were carried
out with Stata Statistical Software, release 13 (Stata-
Corp LP, College Station, Texas).
RESULTS
An overview of the selection process and patient ﬂow
is provided in the Online Figure 1. The initial pooled
population consisted of 7,130 patients. After the
exclusion of patients with prior CABG (n ¼724) or
unavailability of the SYNTAX score (n ¼ 325), 6,081
PCI patients were included in the present analysis.
The cumulative frequency and the distribution of the
SYNTAX score for each trial is shown in Figure 1.
New- and early-generation DES were used in 4,554
(74.8%) and 1,527 (25.2%) patients, respectively. The
mean SYNTAX score in the overall population was
13.1  8.7 (median 11, interquartile range 7 to 18).
Two-year follow-up was available in 5,912 patients
(97.2%).
Patients allocated to new-generation DES were
older; more frequently had a history of diabetes, hy-
pertension, or previous PCI; and were less likely to
have smoking habits, a family history of CAD, or
previous myocardial infarction (Table 1). Angio-
graphic and procedural characteristics indicated a
FIGURE 2 SYNTAX Score Frequency in Patients Treated With
New- and Early-Generation DES
DES ¼ drug-eluting stent(s); SYNTAX ¼ Synergy between Percu-
taneous Coronary Intervention with Taxus and Cardiac Surgery.
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1661higher complexity among patients receiving new-
generation DES (Table 2), also reﬂected by a higher
SYNTAX score (13.3  8.9 vs. 12.5  8.0; p ¼ 0.003).
The cumulative frequency of SYNTAX score amongTABLE 3 Baseline Clinical Characteristics According to SYNTAX Score
SYNTAX Score
New-Generation
DES
(n ¼ 2,253)
Early-Gene
DES
(n ¼ 80
Age, yrs 63.6  11.2 61.6  1
Female 583 (25.9) 197 (24
Body mass index, kg/m2 27.6  4.4 27.6 
Diabetes 447 (19.8) 146 (18
Insulin-requiring 130 (5.8) 42 (5.
Hypertension 1569 (69.7) 521 (65
Hypercholesterolemia 1462 (64.9) 493 (61
Renal failure 265 (12.2) 82 (12
GFR, ml/min 86.4  32.5 86.8  2
Current smoker 675 (30.0) 284 (36
Family history of CAD 667 (31.5) 329 (41
Previous MI 475 (21.2) 228 (28
Previous PCI 647 (28.7) 209 (26
Left ventricular ejection fraction, % 57.6  11.1 58.6  1
Clinical presentation
Stable CAD 928 (43.3) 382 (47
NSTE-ACS 839 (39.2) 281 (35
ST-segment elevation MI 376 (17.5) 137 (17
SYNTAX score 6.3  2.9 6.5  2
Values are mean  SD or n (%).
Abbreviations as in Table 1.patients treated with new- and early-generation DES
is displayed in the Figure 2. Baseline clinical, angio-
graphic, and procedural characteristics in patients
with low (SYNTAX score #11; n ¼ 3,053) versus high
CAD complexity (SYNTAX score >11; n ¼ 3,028) are
shown in Tables 3 and 4. In the group with low CAD
complexity, the mean SYNTAX score was 6.3  2.9
in patients treated with new-generation DES and 6.5
 2.9 in patients treated with early-generation DES
(p ¼ 0.153). In the group with high CAD complexity,
the mean SYNTAX score was 20.2  7.4 in patients
treated with new-generation DES and 19.2  6.5 in
patients treated with early-generation DES (p ¼
0.001). The mean SYNTAX score in patients with
diabetes mellitus and in patients undergoing single-
vessel or multivessel PCI at the time of the index
procedure is reported in Online Table 2.
CLINICAL OUTCOMES IN THE OVERALL POPULATION.
Clinical outcomes at 2 years for the overall compari-
son of new- versus early-generation DES are reported
in Table 5. The primary composite endpoint occurred
less frequently among patients receiving new-
generation compared to those treated with early-
generation DES (10.4% vs. 13.2%; HRadj: 0.75 [95%
CI: 0.63 to 0.89]; p < 0.001) (Figure 3A). New-
generation DES were associated with a lower risk of#11 SYNTAX Score >11
p Value for
Interaction
ration
0) p Value
New-Generation
DES
(n ¼ 2,301)
Early-Generation
DES
(n ¼ 727) p Value
0.8 <0.001 65.5  11.1 64.0  11.2 0.002 0.498
.6) 0.509 534 (23.2) 183 (25.2) 0.293 0.206
4.3 0.616 27.7  4.4 27.3  4.1 0.025 0.210
.3) 0.349 565 (24.6) 152 (20.9) 0.045 0.478
3) 0.655 200 (8.7) 59 (8.1) 0.704 0.917
.1) 0.019 1591 (69.2) 477 (65.6) 0.075 0.720
.6) 0.103 1453 (63.1) 441 (60.7) 0.235 0.765
.1) 1.000 360 (16.3) 90 (14.6) 0.320 0.509
4.6 0.764 84.1  25.5 83.3  26.1 0.514 0.515
.3) 0.001 642 (27.9) 228 (32.2) 0.033 0.498
.1) <0.001 680 (32.1) 277 (38.1) 0.004 0.216
.5) <0.001 568 (25.0) 204 (28.1) 0.108 0.079
.1) 0.169 650 (28.2) 178 (24.5) 0.050 0.636
0.4 0.037 54.6  12.2 53.8  12.5 0.205 0.020
0.077 0.004 <0.001
.8) 0.033 824 (37.9) 266 (36.6) 0.536
.1) 0.050 839 (38.6) 247 (34.0) 0.027
.1) 0.827 511 (23.5) 214 (29.4) 0.002
.9 0.153 20.2  7.4 19.2  6.5 0.001
TABLE 4 Angiographic and Procedural Characteristics According to SYNTAX Score
SYNTAX Score #11 SYNTAX Score >11
p Value for
Interaction
New-Generation
DES
(n ¼ 2,253)
Early-Generation
DES
(n ¼ 800) p Value
New-Generation
DES
(n ¼ 2,301)
Early-Generation
DES
(n ¼ 727) p Value
GPI use 234 (10.4) 184 (23.0) <0.001 441 (19.2) 251 (34.5) <0.001 0.30
Treated lesions per patient 1.26  0.52 1.27  0.52 0.76 1.70  0.87 1.56  0.75 0.011 0.0495
Multivessel treatment per patient 280 (12.4) 102 (12.8) 0.82 796 (34.6) 175 (24.1) <0.001 <0.001
Lesions, n 2,846 1,018 3,918 1,134
Target vessel location per lesion 0.12 <0.001 <0.001
Right coronary artery 1,057 (37.3) 402 (39.5) 1,112 (28.4) 322 (28.4)
Left main artery 9 (0.3) 2 (0.2) 66 (1.7) 10 (0.9)
Left anterior descending artery 1,046 (36.9) 394 (38.7) 1,839 (47.0) 581 (51.2)
Left circumﬂex artery 720 (25.4) 220 (21.6) 890 (22.8) 221 (19.5)
Graft 0 (0.0) 0 (0.0) 4 (0.1) 0 (0.0)
De novo per lesion 2622 (92.9) 974 (95.8) 0.004 3,667 (94.4) 1,087 (96.0) 0.066 0.48
Occlusion per lesion 148 (5.3) 27 (2.7) 0.001 492 (12.7) 121 (10.8) 0.095 0.034
Number of stents per lesion 1.25  0.58 1.14  0.44 <0.001 1.37  0.72 1.26  0.64 <0.001 0.90
Total stent length per lesion, mm 22.95  13.50 19.42  10.71 <0.001 27.00  16.87 22.82  13.87 <0.001 0.33
Mean stent diameter per lesion, mm 3.02  0.48 2.93  0.52 <0.001 2.97  0.45 2.87  0.35 <0.001 <0.001
Values are n (%) or mean  SD.
Abbreviations as in Table 1.
TABLE 5 Clinical Outcomes at 2 Years
New-
Generation
DES (%)
(n ¼ 4,554)
Early-
Generation
DES (%)
(n ¼ 1,527)
Crude Analysis Adjusted Analysis
HR (95% CI) p Value
p Value for
Interaction HR (95% CI) p Value
p Value for
Interaction
Primary endpoint 0.185 0.219
Overall 462 (10.4) 200 (13.2) 0.78 (0.66–0.92) 0.003 0.75 (0.63–0.89) 0.001
Syntax score #11 175 (8.0) 71 (8.9) 0.89 (0.67–1.17) 0.388 0.86 (0.64–1.16) 0.322
Syntax score >11 287 (12.7) 129 (17.8) 0.70 (0.57–0.86) 0.001 0.68 (0.54–0.85) 0.001
Cardiac death 0.016 0.042
Overall 106 (2.4) 50 (3.3) 0.72 (0.51–1.01) 0.056 0.60 (0.42–0.85) 0.004
Syntax score #11 39 (1.8) 10 (1.3) 1.41 (0.71–2.83) 0.330 1.03 (0.51–2.09) 0.930
Syntax score >11 67 (3.0) 40 (5.5) 0.53 (0.36–0.79) 0.002 0.46 (0.31–0.70) <0.001
Any MI 0.965 0.876
Overall 228 (5.1) 69 (4.6) 1.12 (0.86–1.47) 0.403 1.17 (0.87–1.57) 0.311
Syntax score #11 87 (4.0) 28 (3.5) 1.12 (0.73–1.71) 0.609 1.16 (0.73–1.84) 0.540
Syntax score >11 141 (6.2) 41 (5.7) 1.10 (0.78–1.56) 0.590 1.18 (0.80–1.73) 0.410
Clinically-indicated
TLR
0.083 0.059
Overall 217 (5.0) 129 (8.6) 0.56 (0.45–0.70) <0.001 0.56 (0.44–0.70) <0.001
Syntax score #11 88 (4.1) 45 (5.7) 0.71 (0.49–1.01) 0.060 0.74 (0.50–1.08) 0.117
Syntax score >11 129 (5.9) 84 (11.9) 0.47 (0.36–0.62) <0.001 0.46 (0.34–0.61) <0.001
Clinically-indicated
TVR
0.057 0.039
Overall 277 (6.4) 152 (10.1) 0.61 (0.50–0.74) <0.001 0.61 (0.49–0.75) <0.001
Syntax score #11 110 (5.1) 52 (6.6) 0.76 (0.55–1.06) 0.110 0.81 (0.57–1.15) 0.233
Syntax score >11 167 (7.6) 100 (14.1) 0.51 (0.40–0.65) <0.001 0.51 (0.39–0.66) 0.000
Deﬁnite ST 0.026 0.013
Overall 42 (0.9) 38 (2.5) 0.37 (0.24–0.58) <0.001 0.40 (0.25–0.65) <0.001
Syntax score #11 20 (0.9) 10 (1.3) 0.73 (0.34–1.55) 0.409 0.94 (0.40–2.23) 0.888
Syntax score >11 22 (1.0) 28 (3.9) 0.25 (0.14–0.43) <0.001 0.24 (0.13–0.44) <0.001
Deﬁnite or probable ST 0.041 0.051
Overall 108 (2.4) 44 (2.9) 0.83 (0.59–1.18) 0.307 0.89 (0.60–1.33) 0.575
Syntax score #11 43 (1.9) 11 (1.4) 1.42 (0.73–2.75) 0.301 1.65 (0.77–3.52) 0.200
Syntax score >11 65 (2.9) 33 (4.6) 0.63 (0.41–0.95) 0.028 0.66 (0.41–1.06) 0.083
CI ¼ conﬁdence interval; DES ¼ drug-eluting stent(s); HR ¼ hazard ratio; MI ¼ myocardial infarction; ST ¼ stent thrombosis; TLR ¼ target lesion revascularization; TVR ¼ target vessel revascularization.
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FIGURE 3 Analysis of the Primary, Device-Oriented Clinical Endpoint With
New- Versus Early-Generation DES
(A) Kaplan-Meier time-to-event curves showing the 1-year occurrence of the composite
of cardiac death, myocardial infarction (MI), or ischemia-driven target lesion revascu-
larization (TLR) between the 2 study groups. (B) Cox-regression analysis of the hazard
ratios among new- and early-generation DES according to the severity of disease
(SYNTAX score, plotted on x-axis). The blue shaded area is the beneﬁt associated with
new- versus early-generation DES that persisted across the entire spectrum of SYNTAX
score (p for interaction ¼ 0.95). Early-generation DES patients with a SYNTAX score of
0 were considered to be at a hazard ratio of 1. Abbreviations as in Figure 2.
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1663TLR (5.0% vs. 8.6%; HRadj: 0.56 [95% CI: 0.44 to
0.70]; p < 0.001) (Figure 4A) and deﬁnite ST (0.9% vs.
2.5%; HRadj: 0.40 [95% CI: 0.25 to 0.65]; p < 0.001)
(Figure 5A).
CLINICAL OUTCOMES ACCORDING TO SYNTAX
SCORE. Table 5 summarizes 2-year clinical outcomes
of new- compared with early-generation DES in pa-
tients with SYNTAX score #11 versus >11. There was
no signiﬁcant interaction (p ¼ 0.219) in the treatment
effect of new- versus early-generation DES for the
primary composite endpoint between patients with
SYNTAX score #11 (HRadj: 0.86 [95% CI: 0.64 to 1.16];
p ¼ 0.322) and >11 (HRadj: 0.68 [95% CI: 0.54 to 0.85];
p ¼ 0.001). The reduction in the risk of ischemia-
driven TLR was more evident in patients with SYN-
TAX score >11 (HRadj: 0.46 [95% CI: 0.34 to 0.61]; p <
0.001) than in patients with SYNTAX score #11 (HRadj:
0.74 [95% CI: 0.50 to 1.08]; p ¼ 0.117), although
the interaction test was formally not signiﬁcant
(p ¼ 0.059). Compared with early-generation DES,
new-generation DES did not lower the risk of deﬁnite
ST among patients with SYNTAX score #11 (HRadj:
0.94 [95% CI: 0.40 to 2.23]; p ¼ 0.888), but reduced
the risk among patients with SYNTAX score >11
(HRadj: 0.24 [95% CI: 0.13 to 0.44]; p < 0.001), with a
signiﬁcant interaction (p ¼ 0.013). New-generation
DES were also associated with a lower risk of cardiac
death among patients with SYNTAX score >11 (HRadj:
0.46 [95% CI: 0.31 to 0.70]; p < 0.001) compared with
those with a SYNTAX score #11 (HRadj : 1.03 [95% CI:
0.51 to 2.09]; p ¼ 0.93), with a signiﬁcant interaction
(p ¼ 0.042).
The results of Cox regression analyses, in which
the interaction by the type of DES (new- vs. early-
generation devices) and the SYNTAX score were
tested, are reported in the Online Table 3. The
graphical representations of these ﬁndings are shown
in Figures 3B, 4B, and 5B. Of interest, there was no
signiﬁcant interaction between the effects of new-
versus early-generation DES and the SYNTAX score
for the primary composite endpoint (p ¼ 0.16), TLR
(p ¼ 0.25), and deﬁnite ST (p ¼ 0.11), suggesting that
the improved effectiveness and safety proﬁle of new-
compared with early-generation DES were not
affected by the SYNTAX score. Furthermore, there
was no signiﬁcant interaction between the type of
new-generation DES and the primary endpoints of the
study (Online Table 4), suggesting a consistent effect
within new-generation devices.
DISCUSSION
This study evaluated the safety and effectiveness of
new- compared with early-generation DES accordingto CAD complexity as deﬁned by the SYNTAX score
among 6,081 participants enrolled in 4 all-comer PCI
trials. The principal ﬁndings of this patient-level
pooled analysis are 2-fold:
1. New-generation DES provide greater safety and
effectiveness compared with early-generation DES
in the overall population by reducing the risk of the
primary device-oriented endpoint, ischemia-
driven TLR, and deﬁnite ST; and
FIGURE 4 Analysis of the Principal Effectiveness Endpoint:
Ischemia-Driven Target Lesion Revascularization
(A) Kaplan-Meier time-to-event curves for new- and early-generation DES. (B) Cox
regression analysis of the hazard ratios for TLR among new- and early-generation DES
according to SYNTAX score. Abbreviations as in Figures 2 and 3.
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16642. The anatomic complexity of CAD did not alter
the beneﬁts of new-generation DES, which tended
to be greater in patients with SYNTAX score >11.
Currently DES are indicated as therapy of choice in
nearly all patient and lesion subsets (5). However,
the beneﬁt of new-generation DES has not been
systematically assessed according to the complexity
of the underlying CAD. This is important, as the
treatment effect of new-generation DES may be
camouﬂaged by the overriding effect of the under-
lying CAD. Moreover, early-generation DES failed to
be noninferior to CABG in the SYNTAX and
FREEDOM trials, in whom patients with multivessel
CAD were investigated (10,11). We, therefore, per-
formed the present analysis that, with approximately6,000 patients, represents one of the largest sources
assessing the effect of the SYNTAX score on out-
comes between patients treated with new-generation
compared to those treated with early-generation DES
across a wide spectrum of CAD.
We observed signiﬁcant improvements in the safety
and effectiveness of new- compared with early-
generation DES in the overall population—a ﬁnding
that corroborates results from previous studies (1,4).
Despite a higher baseline risk proﬁle, new-generation
DES were associated with a 25% relative risk reduc-
tion of the primary composite endpoint, as well as
decreased risks of TLR (54%) and deﬁnite ST (60%).
In addition, we analyzed the differential outcome
between new- and early-generation DES in relation
to the underlying CAD severity as assessed by the
SYNTAX score. Our study further extends the ﬁndings
of the LEADERS trial, which reported a trend toward
reduction of deﬁnite ST with biolimus-eluting stents
in more anatomically complex CAD (19). With
increased event rates through 2 years, we found that
new-generation DES were associated with a 76%
relative reduction in the risk of deﬁnite ST in patients
with SYNTAX score >11 compared with patients with
SYNTAX score #11 (p for interaction ¼ 0.013). More-
over, new-generation DES were associated with a
somewhat greater effectiveness in the subgroup of
patients with SYNTAX score >11, as suggested by the
interactiontests forTLR(p¼0.059)andTVR(p¼0.039).
Therefore, the signiﬁcant interaction in the treat-
ment effect between new- and early-generation DES
observed for cardiac mortality (p ¼ 0.015) may be
interpreted as the result of improved safety and effec-
tiveness with new-generation DES in patients with
more advanced CAD severity (20).
The SYNTAX score was initially developed to
quantify the anatomic complexity of coronary le-
sions in the randomized SYNTAX trial that compared
PCI with the use of paclitaxel-eluting stents versus
CABG in patients with left main or 3-vessel disease
(10,17). After validation in the ARTS-II (Arterial
Revascularization Therapies Study part II) (21),
several studies subsequently conﬁrmed its predic-
tive value among patients undergoing PCI (22); its
use is recommended by American and European
guidelines in the decision making process to deter-
mine the optimal revascularization strategy (23,24).
The ﬁnal 5-year results of the SYNTAX trial showed
signiﬁcantly higher rates of the primary composite
endpoint of death, stroke, myocardial infarction, or
repeat revascularization in patients undergoing PCI
compared with CABG, with increasing divergence
between the 2 treatment modalities with higher
SYNTAX score terciles (25). There is broad agreement
FIGURE 5 Analysis of the Principal Safety Endpoint: Deﬁnite Stent Thrombosis
(A) Kaplan-Meier time-to-event curves for new- and early-generation DES. (B) Cox regression analysis of the hazard ratios for stent thrombosis among new- and early-
generation DES according to SYNTAX score. Abbreviations as in Figure 2.
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1665in preferring CABG over PCI in patients with severely
advanced CAD, and current American and European
guidelines on revascularization give preference to
CABG in patients with 3-vessel disease and SYNTAX
score $23 (23,24). As these data as well as those
obtained in the FREEDOM trial were obtained with
early-generation DES, it is tempting to speculate
whether the use of new-generation DES may alle-
viate the existing gap between CABG and early-
generation DES in patients with severe multivessel
disease. Although prematurely terminated after the
enrolment of 880 patients, a recent trial reported a
signiﬁcantly lower risk of death, myocardial infarc-
tion, or TLR among patients with multivessel CAD
randomly allocated to CABG compared with PCI
with the use of the new-generation everolimus-
eluting stent (26). The beneﬁt in favor of CABG was
driven by a lower risk of repeat revascularization,
due to a higher risk of non-TLR among PCI-treated
patients (26).
STUDY LIMITATIONS. First, although this study
supported the superiority of new- compared with
early-generation DES across the range of CAD
complexity, our results cannot be extrapolated to
strategies trials comparing PCI with CABG. Indeed,
patients with SYNTAX score in the intermediate or
high terciles ($23) were under-represented in the
study, and conclusions drawn in this population
should be considered hypothesis generating andpreliminary. Second, the graphical representation of
the interaction between the type of DES and the
SYNTAX score should be interpreted in view of the
limitation of any post-estimation model. Third, we
were unable to compare outcomes associated with
new-generation DES against a CABG arm. Therefore,
the results of our study should be considered
hypothesis-generating in view of ongoing random-
ized trials of PCI with new-generation DES vs. CABG
(NCT01205776, NCT02100722).
CONCLUSIONS
New-generation DES improve clinical outcomes
compared with early-generation DES at 2-year follow-
up. The therapeutic beneﬁt of new- compared with
early-generation DES in terms of safety and effec-
tiveness was not diminished in patients with
increased anatomic CAD complexity but tended to be
more evident in patients with SYNTAX score >11.
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PERSPECTIVES
WHAT IS KNOWN? New-generation DES are associated
with improved safety and efﬁcacy compared with early-
generation DES.
WHAT IS NEW? Complexity of underlying CAD as
deﬁned by the angiographic SYNTAX score does not
affect the beneﬁts of new- over early-generation DES.
The effectiveness and safety of new- over early-
generation DES may be more pronounced among patients
with moderate to high anatomic complexity.
WHAT IS NEXT? The use of new-generation DES is
expected to improve clinical outcomes irrespective of the
SYNTAX score. New-generation DES have the potential
to reduce the existing gap between percutaneous and
surgical myocardial revascularization in patients with
advanced CAD.
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